Cargando…

BRD4‐IRF1 axis regulates chemoradiotherapy‐induced PD‐L1 expression and immune evasion in non‐small cell lung cancer

BACKGROUND: Chemoradiotherapy‐induced PD‐L1 upregulation leads to therapeutic resistance and treatment failure. The PD‐1/PD‐L1 blocking antibodies sensitize cancers to chemoradiotherapy by blocking extracellular PD‐1 and PD‐L1 binding without affecting the oncogenic function of intracellular PD‐L1....

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Jian, Xu, Yingzhuo, Rao, Xinrui, Zhang, Ruiguang, Tang, Jing, Zhang, Dan, Jie, Xiaohua, Zhu, Kuikui, Wang, Xu, Xu, Yunhong, Zhang, Sheng, Dong, Xiaorong, Zhang, Tao, Yang, Kunyu, Xu, Shuangbing, Meng, Rui, Wu, Gang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8792480/ https://www.ncbi.nlm.nih.gov/pubmed/35083874 http://dx.doi.org/10.1002/ctm2.718

Ejemplares similares

PD-1(+) mast cell enhanced by PD-1 blocking therapy associated with resistance to immunotherapy
por: Li, Jun, et al.
Publicado: (2022)

CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 signaling in non-small cell lung cancer
por: Wang, Jian, et al.
Publicado: (2020)

FIBP interacts with transcription factor STAT3 to induce EME1 expression and drive radioresistance in lung adenocarcinoma
por: Xu, Yunhong, et al.
Publicado: (2023)

Targeting KDM4C enhances CD8(+) T cell mediated antitumor immunity by activating chemokine CXCL10 transcription in lung cancer
por: Jie, Xiaohua, et al.
Publicado: (2022)

REV1 promotes lung tumorigenesis by activating the Rad18/SERTAD2 axis
por: Chen, Yunshang, et al.
Publicado: (2022)

Editorial: Targeting the PD-1/PD-L1 Cancer Immune Evasion Axis: Challenges and Emerging Strategies
por: Wang, Yiting, et al.
Publicado: (2020)

RelB upregulates PD-L1 and exacerbates prostate cancer immune evasion
por: Zhang, Yanyan, et al.
Publicado: (2022)

The Research Progress of PD-1/PD-L1 Inhibitors Enhancing Radiotherapy Efficacy
por: Wen, Lu, et al.
Publicado: (2021)

Transcriptome-Based Co-Expression of BRD4 and PD-1/PD-L1 Predicts Poor Overall Survival in Patients With Acute Myeloid Leukemia
por: Chen, Cunte, et al.
Publicado: (2021)

Editorial: Targeting the PD-1/PD-L1 cancer immune evasion axis: Challenges and emerging strategies, Volume II
por: He, Xiujing, et al.
Publicado: (2022)

BRD4 Targets the KEAP1-Nrf2-G6PD Axis and Suppresses Redox Metabolism in Small Cell Lung Cancer
por: Lv, Yang, et al.
Publicado: (2022)

PRDM1/BLIMP1 induces cancer immune evasion by modulating the USP22-SPI1-PD-L1 axis in hepatocellular carcinoma cells
por: Li, Qing, et al.
Publicado: (2022)

β-Trcp and CK1δ-mediated degradation of LZTS2 activates PI3K/AKT signaling to drive tumorigenesis and metastasis in hepatocellular carcinoma
por: Lu, Yanwei, et al.
Publicado: (2021)

Molecular dynamics simulations data of six compounds F3J-BRD4/CBP, EX1-BRD4/CBP, and E2T-BRD4/CBP
por: Wu, Shiliang, et al.
Publicado: (2021)

Activated amino acid response pathway generates apatinib resistance by reprograming glutamine metabolism in non-small-cell lung cancer
por: Zhou, Xiaoshu, et al.
Publicado: (2022)

Targeting ADRB2 enhances sensitivity of non-small cell lung cancer to VEGFR2 tyrosine kinase inhibitors
por: Xu, Yingzhuo, et al.
Publicado: (2022)

Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion
por: Wang, Yiting, et al.
Publicado: (2018)

Cyclin K interacts with β-catenin to induce Cyclin D1 expression and facilitates tumorigenesis and radioresistance in lung cancer
por: Yao, Guojun, et al.
Publicado: (2020)

USP9X-mediated KDM4C deubiquitination promotes lung cancer radioresistance by epigenetically inducing TGF-β2 transcription
por: Jie, Xiaohua, et al.
Publicado: (2021)

CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis
por: Yang, Hui, et al.
Publicado: (2020)

Self‐Cooperative Prodrug Nanovesicles Migrate Immune Evasion to Potentiate Chemoradiotherapy in Head and Neck Cancer
por: Zhu, Yun, et al.
Publicado: (2022)

Disrupting the phase separation of KAT8–IRF1 diminishes PD-L1 expression and promotes antitumor immunity
por: Wu, Yuanzhong, et al.
Publicado: (2023)

Sphingosine kinase 1 promotes tumor immune evasion by regulating the MTA3-PD-L1 axis
por: Lau, Poyee, et al.
Publicado: (2022)

Anti-PD-1 sintilimab-induced bilateral optic neuropathy in non-small cell lung cancer: A case report and literature review
por: Wang, Jian, et al.
Publicado: (2022)

PD-1/PD-L1 Correlates With the Efficacy of the Treatment of Concurrent Chemoradiotherapy in Cervical Cancer
por: Zhang, Hanqun, et al.
Publicado: (2022)

NLRP6 is required for cancer-derived exosome-modified macrophage M2 polarization and promotes metastasis in small cell lung cancer
por: Rao, Xinrui, et al.
Publicado: (2022)

Immune evasion strategy involving propionylation by the KSHV interferon regulatory factor 1 (vIRF1)
por: Shi, Jiale, et al.
Publicado: (2023)

TRIM14 expression is regulated by IRF‐1 and IRF‐2
por: Cui, Jingang, et al.
Publicado: (2019)

TP53/mTORC1-mediated bidirectional regulation of PD-L1 modulates immune evasion in hepatocellular carcinoma
por: Yu, Jiongjie, et al.
Publicado: (2023)

Bromodomain protein Brd3 promotes Ifnb1 transcription via enhancing IRF3/p300 complex formation and recruitment to Ifnb1 promoter in macrophages
por: Ren, Wenhui, et al.
Publicado: (2017)

β-Catenin induces transcriptional expression of PD-L1 to promote glioblastoma immune evasion
por: Du, Linyong, et al.
Publicado: (2020)

S6K1 phosphorylation-dependent degradation of Mxi1 by β-Trcp ubiquitin ligase promotes Myc activation and radioresistance in lung cancer
por: Huang, Yumei, et al.
Publicado: (2018)

Circulating PD‐1 (+) cells may participate in immune evasion in peripheral T‐cell lymphoma and chidamide enhance antitumor activity of PD‐1 (+) cells
por: Zhang, Wei, et al.
Publicado: (2019)

O-GlcNAcylation promotes tumor immune evasion by inhibiting PD-L1 lysosomal degradation
por: Zhu, Qiang, et al.
Publicado: (2023)

FGFR2–BRD4 Axis Regulates Transcriptional Networks of Histone 3 Modification and Synergy Between Its Inhibitors and PD-1/PD-L1 in a TNBC Mouse Model
por: Lei, Josh Haipeng, et al.
Publicado: (2022)

CRISPR screening identifies the deubiquitylase ATXN3 as a PD-L1–positive regulator for tumor immune evasion
por: Wang, Shengnan, et al.
Publicado: (2023)

RIG-I promotes immune evasion of colon cancer by modulating PD-L1 ubiquitination
por: Zhang, Yangyang, et al.
Publicado: (2023)

PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy
por: Xu, Yiqi, et al.
Publicado: (2021)

Author Correction: Bromodomain protein Brd3 promotes Ifnb1 transcription via enhancing IRF3/p300 complex formation and recruitment to Ifnb1 promoter in macrophages
por: Ren, Wenhui, et al.
Publicado: (2020)

Ferritinophagy is required for the induction of ferroptosis by the bromodomain protein BRD4 inhibitor (+)-JQ1 in cancer cells
por: Sui, Shiyao, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_sj0ucr5d83o35ltohqaqchpv5m